珠海市海瑞德生物科技有限公司

公司主营业务为原料药及其中间体的研发、生产和销售。产品应用到抗病毒，抗凝血，抗抑郁，抗癫痫，胃肠道疾病，糖尿病及抗过敏等多个领域，如磷酸奥司他韦及其中间体、依度沙班及其中间体、富马酸沃诺拉赞及其中间体、磷酸特地唑胺及其中间体、达格列净和卡格列净及其中间体、马来酸氟伏沙明及其中间体、唑尼沙胺及其中间体、非马沙坦及其中间体、艾普拉唑及其中间体、马来酸卡比沙明及其中间体等。公司通过ISO9001质量管理体系和多次国内外客户现场审计，产品远销东南亚，日韩，中东和南美等市场。

2019年海瑞德在金湾区高栏港国家化工园区投资2.5亿元建设新GMP厂区，一期厂房占地42亩，建有6个高标准多层原料药车间，年产能达300吨。新厂区严格按照CGMP标准设计建造，将建立起符合ICH,欧盟及美国FDA高标准质量体系，预计2022年中旬投入使用。

公司坚持以“开发并生产前沿原料药及中间体”为企业发展目标，坚持“追求卓越产品品质和合理低成本，力求为患者健康事业创造最大价值”的经营宗旨，不断完善企业的经营管理体系和优化产品生产工艺，致力于创建具有自身特色生产经营体系。
 

Zhuhai Hairuide Bioscience and Technology Co., Ltd., was established in February 2009 with a registered capital of 20 million RMB, which is located in the medical base of Jinwan District, Zhuhai. Our company is an integrated firm includes the research, production and sales of pharmaceutical raw materials with its’ intermediate,with 6 registered intellectual property rights.

The production area covers about 6000 square meters. We are good at the Grignard reaction, ultra-low temperature reaction (-80℃), anhydrous and oxygen-free reaction, core technology development and its optimization, having the ability with completed facility for the pilot and commercial production.

Our main business is the research, production and sales of the APIs and its’ intermediates,which covers the fields of antiviral, anticoagulant, antidepressant, antiepileptic, gastrointestinal disease, diabetes and antiallergic ect. Such as Oseltamivir Phosphate and its intermediates, Edoxaban and its intermediates, Vonourazan Fumarate and its intermediates, Tedizolid Phosphate and its intermediates, Dapagliflozin and Canagliflozin and their intermediates, Fluvoxamine Maleate and its intermediates, Zonisamide and its intermediates, Fimasartan and its intermediates, ilaprazole and its intermediates, Carbinoxamine Maleate Salt and its intermediates etc.

Our company has achieved the ISO9001 quality management system certificate and passed many on-site audits by domestic and international customer, and the products are exported to Southeast Asia,Korea,Japan, Middle East and South America.

In 2019, our company invested 250 million RMB for construction an new GMP factory located at Gaolan Port National Chemical Park in Jinwan District. The first phase of the factory has built 6 high-standard multi-layer API workshops covers an area of 42 acres,and its capacity is 300 tons/year. The new plant is designed and constructed in strict accordance with CGMP standards, will build its’ quality system that meets ICH, EU and US FDA standards. It is expected to be launched for production in mid-2022.

Our company adheres to the goal of "Development and Production of cutting-edge APIs and intermediates" as enterprise development, adheres to the tenet of "Pursuing the qualify and affordable product, and creating the greatest value and health for patients". We constantly improves our management system and optimize the production process to create the high quality,affordable and safe medicine for the world.